about Francesco Peri

Francesco Peri

Francesco Peri is full Professor in of Organic and Medicinal Chemistry at the Department of Biotechnology and Biosciences, University of Milano-Bicocca.

He has a permanent professorship at the Ecole Normale Supérieure (ENS) of Lyon (France) where he teaches a course of Medicinal Chemistry (Master level). In 2012, professorship in Organic Chemistry at the University Paris 5, and in 2012 he was Visiting Professor at the Department of Chemistry, University of California, Davis (USA).

Francesco Peri metrics (Google Scholar)

He coordinates (2015-2018) the H2020-funded MSCA-ETN project TOLLerant (“Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach”, GA number 642157). The TOLLerant consortium  is composed by 8 academic and 2 industrial partners belonging to different European countries. The research of the network focuses on the development of new chemical entities able to modulate the activity of Toll-like Receptor 4 (TLR4) for therapeutic and basic research purposes.

The research interests of Peri’s group span the disciplines of organic, bioorganic and medicinal chemistry with an emphasis of study of the interactions between small molecules and their biological (pharmacological) targets. In last ten years, innovative hit and lead compounds for drug discovery were projected and synthesized. These molecules were also used as “chemical genetics” tools to study, in collaboration with biologists and immunologists, some important signal pathways in humans.

The research activity of the lab focused in last year in the design, synthesis and biological characterization of small molecules (mainly cationic and anionic glycolipids) able to modulate the activity of the Toll Like Receptor 4 (TLR4) in the perspective to develop new generations of TLR-directed therapeutics.

Active research projects:

1) Synthesis and biological characterization of new molecules active on TLR4 signaling.

2) New anti-inflammatory compounds targeting TLRs, including compounds targeting IBDs, neuro-inflammations, Amyotrophic Lateral Sclerosis (ALS) and Rheumatoid Arthritis (in collaboration with Rottapharm Biotech (Monza, Italy).

3) New vaccine adjuvants based on TLR4 agonists (in collaboration with Lofarma, Milano).

4) New leads for cardiac drugs based on steroid structures (in collaboration with CVie Therapeutics (Taiwan).

Also visit his  paintings site